Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: health insurance

Medicalwriters/Science Source

Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

Bryn Nelson, PhD  |  June 15, 2020

As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…

Filed under:Biologics/DMARDsResearch Rheum Tagged with:Arthritis & Rheumatologydrug costsinfliximab

Advocacy in a COVID-19 America

Ellen M. Gravallese, MD  |  June 15, 2020

These are truly extraordinary times. The COVID-19 pandemic has affected the rheumatology community, both providers and patients, in many ways, and our advocacy efforts are now more important than ever to ensure policymakers hear us and help address the issues facing our community. As with so many things during this pandemic, we are reimagining advocacy…

Filed under:Legislation & AdvocacyPresident's PerspectiveTechnology Tagged with:COVID-19RheumPAC

U.S. Insurers Often Limit Biosimilar Coverage

Lisa Rapaport  |  May 29, 2020

(Reuters Health)—U.S. commercial health plans only covered biosimilar treatments as preferred products in 14% of coverage decisions last year, according to an analysis of publicly available data on coverage decisions.1 Researchers examined records from the Tufts Medical Center Specialty Drug Evidence and Coverage (SPEC) database, which has information on coverage decisions made by 17 of…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsHealth Insuranceinfliximab-abdainfliximab-dyybpharmacy benefit managers (PBMs)

Some Telemedicine Barriers Are Down During COVID-19 Pandemic

Larry Beresford  |  May 15, 2020

Telerheumatology—which refers to the application of electronic communication technology to clinical encounters from a distance between rheumatologists and their patients—has the potential to extend a workforce projected to experience significant shortfalls, making it more accessible to more patients. Multiple barriers that stood in the way of taking full advantage of this promise are now down—at…

Filed under:Practice SupportTechnology Tagged with:Centers for Medicare & Medicaid Services (CMS)telemedicinetelerheumatology

Capitol Hill Rheumatology Advocacy Goes Virtual

Carina Stanton  |  May 11, 2020

ACR volunteer leaders and staff will convene more than 100 meetings via teleconference with Congressional leaders on May 22, addressing rheumatology provider solvency and patient access to care amidst the COVID-19 pandemic.

Filed under:American College of RheumatologyLegislation & Advocacy Tagged with:Blair SolowCapitol Hill fly-inDan RedingerJessica FarrellLegislation & AdvocacyLennie ShewmakerVirtual Hill Day

Reimbursement Tips: Telemedicine & Coding in the Time of COVID-19

Kimberly Retzlaff  |  April 24, 2020

Humans may fear change as a general rule, but we’re adaptable when we need to be. In this era of COVID-19 and social distancing, medical practices and payers are adapting to an increased use of telemedicine, which enables providers to see their patients without being in a room with them. To cope, the Centers for…

Filed under:Billing/CodingConditionsPractice Support Tagged with:CodingCOVID-19telemedicine

How to Maintain Connections with Colleagues, Staff & Patients During a Pandemic: A Q&A with Reshma Khan, MD

Linda Childers  |  April 17, 2020

As the cases of COVID-19 continue to rise in South Florida, Reshma Khan, MD, a rheumatologist at the Palm Beach Rheumatology and Wellness Center, Jupiter, Fla., is being careful to emphasize social distancing, but not social isolation. Dr. Khan believes that, during this pandemic, it’s more important than ever for rheumatologists to share support and…

Filed under:Professional Topics Tagged with:coronavirusCOVID-19Practice Managementrheumatologiststelemedicine

The COVID-19 Crisis: Uncharted Waters & the ACR’s Response

Ellen M. Gravallese, MD  |  April 15, 2020

Singer Jimmy Dean reportedly once said, “I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” The COVID-19 pandemic has required us as rheumatologists to adjust our sails multiple times. We have had to rethink many of the ways in which we interact with our worried…

Filed under:American College of RheumatologyPresident's PerspectiveProfessional Topics Tagged with:COVID-19

Experts Offer Tips for Saving Time on Electronic Medical Records

Thomas R. Collins  |  April 15, 2020

ATLANTA—“Bane of our existence” and “pajama time”—the dreaded time spent at night catching up on documentation—are a couple of phrases associated with the electronic medical record (EMR). To try to ease the frustration and limit the amount of time physicians have to spend using the systems, two experts reviewed tools and tricks for Epic and…

Filed under:EMRsMeeting ReportsTechnology Tagged with:2019 ACR/ARP Annual Meeting

Yes, the FDA Employs Rheumatologists. Here’s Their Role.

Renée Bacher  |  April 15, 2020

Ever wonder what role physician regulators—rheumatologists, in particular—perform at the U.S. Food & Drug Administration (FDA)? “I am not sure that many practicing rheumatologists know there are clinicians who work for the FDA,” says rheumatologist Nadia Habal, MD, a medical officer in the Division of Pulmonary, Allergy, and Rheumatology Products at the FDA. “It would…

Filed under:Drug Updates Tagged with:U.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 70
  • 71
  • 72
  • 73
  • 74
  • …
  • 117
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences